Inactive Instrument

Press Releases Aquinox Pharmaceuticals Inc Nasdaq

Equities

US03842B1017

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting	Apr. 22	BU
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates	Mar. 18	BU
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	Mar. 04	BU
Neurogene to Participate in Upcoming Investor Conferences	Feb. 29	BU
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	Jan. 16	BU
Neurogene Announces Business Update and 2024 Outlook	Jan. 05	BU
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million	Dec. 20	AQ
Neoleukin Therapeutics : Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome - Form 8-K	Dec. 19	PU
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split	Dec. 14	AQ
Neoleukin: Q3 Earnings Snapshot	Nov. 14	AQ
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split	23-09-22	GL
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split	23-09-22	AQ
NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX	23-07-25	BU
Shareholder Alert: Ademi LLP investigates whether Neoleukin Therapeutics, Inc. has obtained a Fair Price in its Private Placement and its transaction with Neurogene	23-07-18	PR
NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders	23-07-18	BU
Neurogene and Neoleukin Announce Definitive Merger Agreement	23-07-18	GL
Neoleukin: Q1 Earnings Snapshot	23-05-09	AQ
NEOLEUKIN THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	23-05-08	AQ
NEOLEUKIN THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	23-04-03	AQ
NEOLEUKIN THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Aquinox Pharmaceuticals Inc Nasdaq

Equities

US03842B1017

Press Releases

Filters